drugset / Trial / NCT00005632
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Phase 1
Completed
27 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Combining a vaccine with QS21 may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus immune adjuvant QS21 in treating patients who have prostate cancer.
Timeline
- Start
- 1999-06
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | QS-21 | Other / unclassified | 3 ug | Subcutaneous |
| Background | QS-21 | Other / unclassified | — | Subcutaneous |